Murray R
Bull World Health Organ. 1969;41(3):495-6.
The Division of Biologics Standards of the National Institutes of Health made the Hong Kong variant of influenza virus available to US manufacturers for study in August 1968 and provided them with the Aichi strain for production purposes on 9 September. The first lot of vaccine was released on 15 November; 15 million doses had been released by the peak of the epidemic, which occurred in the first week of January 1969 in the USA, and 20 million doses by the end of that month. Despite the tremendous effort made, however, it is questionable whether the use of the vaccine, necessarily in smaller quantities than the total released, had any detectable effect on the course of the 1968-69 epidemic. The author suggests that it is also doubtful whether the 1957 epidemic of Asian influenza in the USA was significantly affected by the larger amount of vaccine that was then available before the epidemic peak was reached. He stresses that priority must be given to research into the problem of making sufficient vaccine available in good time to counter a threatened influenza epidemic.
美国国立卫生研究院生物制品标准司于1968年8月向美国制造商提供了香港流感病毒变种以供研究,并于9月9日向他们提供了用于生产的爱知毒株。第一批疫苗于11月15日发布;到1969年1月美国疫情高峰期,已发布了1500万剂,到该月底已发布了2000万剂。然而,尽管付出了巨大努力,但使用的疫苗数量必然少于总发布量,它是否对1968 - 1969年疫情的发展产生了任何可察觉的影响仍值得怀疑。作者还认为,1957年美国亚洲流感疫情在达到疫情高峰之前就有了更多可用疫苗,它是否受到显著影响也值得怀疑。他强调,必须优先研究及时提供足够疫苗以应对潜在流感疫情这一问题。